Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2006 to 31 December 2006

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1]*)*

(2007/C 18/02)

— Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
4.12.2006	Naglazyme	BioMarin Europe Limited Axtell House 23-24 Warwick Street London W1B 5NQ United Kingdom	EU/1/05/324/001	6.12.2006
4.12.2006	Kaletra	Abbott Laboratories Ltd Queenborough Kent ME11 5EL	EU/1/01/172/001-005	8.12.2006
11.12.2006	Rotarix	GlaxoSmithKline Biologicals s.a. rue de l'Institut 89 B-1330 Rixensart	EU/1/05/330/001-004	13.12.2006
18.12.2006	NeoSpect	CIS bio international Route Nationale 306 Saclay Boîte Postale 32 F-91192 Gif-sur-Yvette	EU/1/00/154/001-002	21.12.2006
18.12.2006	Viracept	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/97/054/003-004 EU/1/97/054/006	20.12.2006
18.12.2006	ATryn	LEO Pharma A/S Industriparken 55 DK-2750 Ballerup Genzyme Europe B.V. Gooimeer 10 1411 DD Naarden Nederland	EU/1/06/355/001-003	20.12.2006
19.12.2006	SonoVue	Bracco International B.V. Strawinskylaan 3051 1077ZX Amsterdam Nederland	EU/1/01/177/001	21.12.2006

[1] OJ L 136 of 30.4.2004, p. 1.

— **Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted**

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
18.12.2006	PRAC-TIC	pyriprole	Novartis Sanidad Animal S.L. Calle de la Marina, 206 E-08013 Barcelona	EU/2/06/066/001-012	Spot-on solution	QP53AX26	20.12.2006
20.12.2006	Medicinal Oxygen Air Liquide Santé	Oxygen	Air Liquide Santé International 10 rue Cognacq-Jay F-75341 Paris Cedex 07	EU/2/06/067/001-002	Inhalation gas	QV03AN01	22.12.2006
19.12.2006	ProMeris	Metaflumizone	Fort Dodge Animal Health Holland C.J. van Houtenlaan 36 1381 CP Weesp Nederland	EU/2/06/064/001-004	Spot-on solution	QP 53AX25	22.12.2006
19.12.2006	ProMeris Duo	Metaflumizone, Amitraz	Fort Dodge Animal Health Holland C.J. van Houtenlaan 36 1381 CP Weesp Nederland	EU/2/06/065/001-010	Spot-on solution	QP 53AD51	21.12.2006

— **Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Rejected**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
11.12.2006	Veraflox	Bayer HealthCare AG D-51368 Leverkusen	-	14.12.2006

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
7, Westferry Circus, Canary Wharf
London E14 4HB
United Kingdom